Coinfection

HIV/HCV Coinfected People with Insulin Resistance Do Not Respond as Well to Interferon-based Therapy

After controlling for other risk factors, insulin resistance was an independent predictor of poor response to interferon plus ribavirin combination therapy for chronic hepatitis C in people with HIV, according to a Spanish study published in the June 23, 2010 Journal of Acquired Immune Deficiency Syndromes. The researchers suggested that management of insulin resistance may enhance response rates in the HIV/HCV coinfected population.

Read more:

Liver Steatosis in People with HIV/HCV Coinfection

HIV positive people with chronic hepatitis C virus (HCV) coinfected do not appear more likely to have hepatic steatosis, or fat accumulation in liver cells, than HIV positive individuals, according to a meta-analysis reported in the July 2010 issue of Hepatology. The analysis also saw no association with any class of antiretroviral drugs.

alt

Read more:

EASL 2010: Pegylated Interferon plus Ribavirin Works as Well in HIV/HCV Coinfected Patients with Cirrhosis

HIV/HCV coinfected patients with cirrhosis who received standard chronic hepatitis C therapy using pegylated interferon plus ribavirin had a sustained virological response rate similar to that of non-cirrhotic coinfected patients, according to research presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna.

alt

Read more:

Reappearance of HCV in Gay Men Is Usually Due to Re-infection, Not Late Relapse

Re-emergence of hepatitis C virus (HCV) in gay and bisexual men who were previously treated and achieved sustained virological response with interferon-based therapy appears to be due to reinfection, not late relapse occurring after the usual window for determining a cure, according to a genetic sequencing study described in the April 1, 2010 Journal of Acquired Immune Deficiency Syndromes.

Read more:

EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin

HIV positive people with acute hepatitis C treated with pegylated interferon plus ribavirin, and HIV negative people treated with pegylated interferon alone, had a similar likelihood of achieving rapid virological response (RVR) at week 4 and sustained virological response (SVR) after completing treatment, according to findings presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. RVR was the best predictor of SVR, but HIV/HCV coinfected patients had larger HCV viral load reductions between weeks 4 and 12, suggesting that ribavirin promotes "third phase" viral decline.

alt

Read more:

HIV/HCV Coinfection Does Not Impair Virological or Immunological Response to Antiretroviral Therapy

HIV positive patients coinfected with hepatitis C virus (HCV) achieved HIV viral load suppression and CD4 cell recovery on antiretroviral therapy similar to that of people with HIV alone, according to a study from China described in the June 1, 2010 Journal of Acquired Immune Deficiency Syndromes. Coinfected individuals with detectable HCV antibodies and HCV RNA, however, appeared more likely to experience certain antiretroviral side effects.

Read more:

EASL 2010: HIV and Hepatitis C Virus Coinfection May Increase Death of CD4 T-cells

Dual infection with HIV and hepatitis C virus (HCV) may promote heightened apoptosis, or programmed death, of CD4 T-cells, according to a poster presented last month at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) in Vienna. This may help explain the finding in some studies that HIV/HCV coinfected people tend to experience more rapid HIV disease progression and have smaller CD4 cell gains on antiretroviral therapy (ART) than those with HIV alone.

Read more:

Screening for Liver Cancer in HIV/HCV Coinfected People

Nearly half of HIV/HCV coinfected individuals with liver cancer in an international study were never screened for hepatocellular carcinoma, but those who did undergo screening had their cancer detected at an earlier stage, leading to more effective treatment and improved survival, according to a report presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna.

Read more:

EASL 2010: Child-Pugh Score Changes Do Not Predict Liver Failure among HIV/HCV Coinfected Patients during Hepatitis C Treatment

Changes in Child-Pugh score, a clinical measure used to indicate the level of liver damage and risk of hepatic decompensation, may not reliably predict liver failure in HIV positive people with chronic hepatitis C virus (HCV) coinfection, since changes in the component parameters may be due to other causes, according to a poster presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna.

Read more: